导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 7.56% | 877/4773 |
| 近一周 | -1.71% | 666/5462 |
| 近一月 | -2.62% | 1345/5421 |
| 近一季 | -3.97% | 1513/5209 |
| 近半年 | -2.80% | 2029/4920 |
| 近一年 | 12.79% | 823/4366 |
| 近两年 | 81.08% | 796/2954 |
| 近三年 | 46.25% | 601/2253 |
| 成立以来 | 102.98% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
3.10% 805/4961 |
17.27% 1479/5312 |
- - |
- - |
| 2025 | 30.30% 1334/4813 |
2.23% 1430/3635 |
3.89% 922/4076 |
20.35% 1991/4524 |
1.95% 1137/4813 |
| 2024 | 7.82% 1616/3463 |
-2.71% 1415/2808 |
-5.71% 1787/3014 |
14.96% 1861/3129 |
2.24% 969/3463 |
| 2023 | -3.89% 657/2656 |
8.45% 458/2280 |
-2.92% 711/2385 |
-5.64% 1351/2515 |
-3.27% 643/2655 |
| 2022 | -18.77% 753/2207 |
-13.59% 792/1919 |
3.35% 1167/2016 |
-9.92% 326/2113 |
0.97% 1414/2208 |
| 2021 | 29.07% 77/1822 |
4.72% 139/1255 |
10.86% 426/1330 |
9.23% 141/1466 |
1.78% 799/1822 |
| 2020 | - - |
- - |
- - |
15.28% 223/1164 |
3.24% 932/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 中信建投中证500增强A VS. 长安沪深300非周期A(740101) |